An Updated Perspective on Current Prognostic and Predictive Biomarkers in Chronic Lymphocytic Leukemia in the Context of Chemoimmunotherapy and Novel Targeted Therapy.

Cancers (Basel) · 2020 · PMC7226446 · PMID 32272636

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

quite significantno p-value reported

88% for the ibrutinib-rituximab and FCR groups respectively) however, was quite significant for those with UM IGHV (90.7% vs. 62.5%).

also in 5,695 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.